Hospital Pharmacy - October 2017 - 581

Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug cannot
be directly compared to rates in the clinical trials of another drug and
may not reflect the rates observed in practice.

Adverse
Reaction
Pneumonia
(excluding fungal)
Sleep disorders
Bacteremia
(excluding sepsis)
Vomiting
Chills
Hypotension
Non-conduction
cardiotoxicity
Dizziness
Fungal infection
Hypertension
Hypoxia
Upper respiratory
infections (excluding
fungal)
Chest pain
Pyrexia
Catheter/device/
injection site reaction
Delirium
Pleural effusion
Anxiety
Pruritus
Sepsis (excluding
fungal)
Hemorrhoids
Petechiae
Renal insufficiency
Transfusion reactions
Visual impairment
(except bleeding)

The safety of VYXEOS was determined in a randomized trial for adults with
newly-diagnosed t-AML or AML-MRC which included 153 patients treated
with VYXEOS and 151 patients treated with a standard combination of
cytarabine and daunorubicin (7+3). At study entry, patients were required
to have a LVEF of at least 50% and a prior lifetime cumulative anthracycline
exposure less than 368 mg/m2 daunorubicin (or equivalent). On study,
the median number of cycles administered was 2 (range, 1-4 cycles)
on the VYXEOS arm and 1 (range, 1-4 cycles) on the control arm.
The median cumulative daunorubicin dose was 189 mg/m2
(range, 44-337 mg/m2) on the VYXEOS arm and 186 mg/m2
(range, 44-532 mg/m2) on the control arm.
Nine patients each on the VYXEOS arm (6%) and the control arm (6%)
had a fatal adverse reaction on treatment or within 30 days of therapy
that was not in the setting of progressive disease. Fatal adverse reactions
on the VYXEOS arm included infection, CNS hemorrhage, and respiratory
failure. Overall, all-cause day-30 mortality was 6% in the VYXEOS arm
and 11% in the control arm. During the first 60 days of the study, 14%
(21/153) of patients died in the VYXEOS arm vs. 21% (32/151) of patients
in the 7+3 treatment group.
The most common serious adverse reactions (incidence ≥5%) on the
VYXEOS arm were dyspnea, myocardial toxicity, sepsis, pneumonia,
febrile neutropenia, bacteremia and hemorrhage. Adverse reactions
led to discontinuation of VYXEOS in 18% (28/153) of patients, and
13% (20/151) in the control arm. The adverse reactions leading to
discontinuation on the VYXEOS arm included prolonged cytopenias,
infection, cardiotoxicity, respiratory failure, hemorrhage (GI and CNS),
renal insufficiency, colitis, and generalized medical deterioration. The
most common adverse reactions (incidence ≥25%) in patients on
the VYXEOS arm were hemorrhagic events, febrile neutropenia, rash,
edema, nausea, mucositis, diarrhea, constipation, musculoskeletal pain,
fatigue, abdominal pain, dyspnea, headache, cough, decreased appetite,
arrhythmia, pneumonia, bacteremia, chills, sleep disorders, and vomiting.
The incidences of common adverse drug reactions during the induction
phase in Study 1 are presented in Table 2.
Table 2: Common Adverse Reactions (≥10% Incidence
in the VYXEOS arm) During the Induction Phase
Grades 3 to 5a
All Gradesa
Adverse
VYXEOS
7+3
VYXEOS
7+3
Reaction
N=153
N=151
N=153
N=151
n (%)
n (%)
n (%)
n (%)
Hemorrhage
107 (70)
74 (49)
15 (10)
9 (6)
Febrile Neutropenia
104 (68)
103 (68)
101 (66)
102 (68)
Rash
82 (54)
55 (36)
8 (5)
2 (1)
Edema
78 (51)
90 (60)
2 (2)
5 (3)
Nausea
72 (47)
79 (52)
1 (1)
1 (1)
Diarrhea/Colitis
69 (45)
100 (66)
4 (3)
10 (7)
Mucositis
67 (44)
69 (46)
2 (1)
7 (5)
Constipation
61 (40)
57 (38)
0
0
Musculoskeletal pain
58 (38)
52 (34)
5 (3)
4 (3)
Abdominal pain
51 (33)
45 (30)
3 (2)
3 (2)
Cough
51 (33)
34 (23)
0
1 (1)
Headache
51 (33)
36 (24)
2 (1)
1 (1)
Dyspnea
49 (32)
51 (34)
17 (11)
15 (10)
Fatigue
49 (32)
58 (38)
8 (5)
8 (5)
Arrhythmia
46 (30)
41 (27)
10 (7)
7 (5)
Decreased appetite
44 (29)
57 (38)
2 (1)
5 (3)

All Gradesa
VYXEOS
7+3
N=153
N=151
n (%)
n (%)

Grades 3 to 5a
VYXEOS
7+3
N=153
N=151
n (%)
n (%)

39 (26)

35 (23)

30 (20)

26 (17)

38 (25)

42 (28)

2 (1)

1 (1)

37 (24)

37 (25)

35 (23)

31 (21)

37 (24)
35 (23)
30 (20)

33 (22)
38 (25)
32 (21)

0
0
7 (5)

0
0
1 (1)

31 (20)

27 (18)

13 (9)

15 (10)

27 (18)
27 (18)
28 (18)
28 (18)

26 (17)
19 (13)
22 (15)
31 (21)

1 (1)
11 (7)
15 (10)
19 (12)

0
9 (6)
8 (5)
23 (15)

28 (18)

19 (13)

4 (3)

1 (1)

26 (17)
26 (17)

22 (15)
23 (15)

5 (3)
1 (1)

0
2 (1)

24 (16)

15 (10)

0

0

24 (16)
24 (16)
21 (14)
23 (15)

33 (22)
25 (17)
16 (11)
14 (9)

4 (3)
3 (2)
0
0

9 (6)
2 (1)
0
0

17 (11)

20 (13)

n/a

n/a

16 (11)
17 (11)
17 (11)
17 (11)

12 (8)
17 (11)
17 (11)
16 (11)

0
0
7 (5)
3 (2)

0
0
7 (5)
1 (1)

16 (11)

8 (5)

0

0

Adverse reactions were graded using NCI CTCAE version 3.0.

a

During the consolidation phase (both consolidation cycles pooled) the
two most common adverse reactions on the VYXEOS arm are the same
as those during induction, hemorrhagic events and febrile neutropenia.
These occurred at lower rates in the pooled consolidation phase (43%
and 29%, respectively), compared to the induction phase. All of the
common adverse reactions (≥10% incidence in the VYXEOS arm)
seen in the pooled consolidation phase were also seen in the induction
phase. These occurred at lower incidence in the consolidation phase,
with the exception of chills, dizziness and pyrexia, where the
incidences were relatively similar across the induction and
consolidation cycles.
Other notable adverse drug reactions that occurred in less than 10% of
patients treated with VYXEOS during induction or consolidation included:
* Ear and labyrinth disorders: Deafness, Deafness unilateral
* Eye Disorders: Eye conjunctivitis, Dry eye, Eye edema, Eye swelling,
Eye irritation, Eye pain, Ocular discomfort, Ocular hyperemia,
Periorbital edema, Scleral hyperemia
* Gastrointestinal disorders: Dyspepsia
* Psychiatric disorders: Hallucinations
* Respiratory, thoracic and mediastinal disorders: Pneumonitis



Table of Contents for the Digital Edition of Hospital Pharmacy - October 2017

Pharmacists and Medical Missions
Current FDA-Related Drug Information
Summaries of Safety Labeling Changes Approved By FDA- Boxed Warnings Highlights April-June 2017
Pharmaceutical Pipeline Update
Cholesterol Ester Transfer Protein Inhibitor Review
Formulary Drug Review
Ocrelizumab
Patient Outcomes Associated With Phenobarbital Use With or Without Benzodiazepines for Alcohol Withdrawal Syndrome: A Systematic Review
Development of a Pharmacy Technician–Driven Program to Improve Vaccination Rates at an Academic Medical Center
Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Hemodialysis Patients
Multilayer Model of Pharmacy Participation in the Antimicrobial Stewardship Program at a Large Academic Medical Center
Impact of Inpatient Automatic Therapeutic Substitutions on Postdischarge Medication Prescribing
Impact of Respiratory Viral Panel Polymerase Chain Reaction Assay Turnaround Time on Length of Stay and Antibiotic Use in Patients With Respiratory Viral Illnesses
Administration of Injectable Vitamin K Orally
Hospital Pharmacy - October 2017 - 577
Hospital Pharmacy - October 2017 - 578
Hospital Pharmacy - October 2017 - 579
Hospital Pharmacy - October 2017 - 580
Hospital Pharmacy - October 2017 - 581
Hospital Pharmacy - October 2017 - 582
Hospital Pharmacy - October 2017 - 583
Hospital Pharmacy - October 2017 - 584
Hospital Pharmacy - October 2017 - 585
Hospital Pharmacy - October 2017 - 586
Hospital Pharmacy - October 2017 - 587
Hospital Pharmacy - October 2017 - 588
Hospital Pharmacy - October 2017 - Pharmacists and Medical Missions
Hospital Pharmacy - October 2017 - Current FDA-Related Drug Information
Hospital Pharmacy - October 2017 - Summaries of Safety Labeling Changes Approved By FDA- Boxed Warnings Highlights April-June 2017
Hospital Pharmacy - October 2017 - 592
Hospital Pharmacy - October 2017 - Pharmaceutical Pipeline Update
Hospital Pharmacy - October 2017 - Cholesterol Ester Transfer Protein Inhibitor Review
Hospital Pharmacy - October 2017 - 595
Hospital Pharmacy - October 2017 - Formulary Drug Review
Hospital Pharmacy - October 2017 - Ocrelizumab
Hospital Pharmacy - October 2017 - 598
Hospital Pharmacy - October 2017 - 599
Hospital Pharmacy - October 2017 - 600
Hospital Pharmacy - October 2017 - 601
Hospital Pharmacy - October 2017 - 602
Hospital Pharmacy - October 2017 - 603
Hospital Pharmacy - October 2017 - 604
Hospital Pharmacy - October 2017 - Patient Outcomes Associated With Phenobarbital Use With or Without Benzodiazepines for Alcohol Withdrawal Syndrome: A Systematic Review
Hospital Pharmacy - October 2017 - 606
Hospital Pharmacy - October 2017 - 607
Hospital Pharmacy - October 2017 - 608
Hospital Pharmacy - October 2017 - 609
Hospital Pharmacy - October 2017 - 610
Hospital Pharmacy - October 2017 - 611
Hospital Pharmacy - October 2017 - 612
Hospital Pharmacy - October 2017 - 613
Hospital Pharmacy - October 2017 - 614
Hospital Pharmacy - October 2017 - Development of a Pharmacy Technician–Driven Program to Improve Vaccination Rates at an Academic Medical Center
Hospital Pharmacy - October 2017 - 616
Hospital Pharmacy - October 2017 - 617
Hospital Pharmacy - October 2017 - 618
Hospital Pharmacy - October 2017 - 619
Hospital Pharmacy - October 2017 - 620
Hospital Pharmacy - October 2017 - Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Hemodialysis Patients
Hospital Pharmacy - October 2017 - 622
Hospital Pharmacy - October 2017 - 623
Hospital Pharmacy - October 2017 - 624
Hospital Pharmacy - October 2017 - 625
Hospital Pharmacy - October 2017 - Multilayer Model of Pharmacy Participation in the Antimicrobial Stewardship Program at a Large Academic Medical Center
Hospital Pharmacy - October 2017 - 627
Hospital Pharmacy - October 2017 - 628
Hospital Pharmacy - October 2017 - 629
Hospital Pharmacy - October 2017 - 630
Hospital Pharmacy - October 2017 - 631
Hospital Pharmacy - October 2017 - 632
Hospital Pharmacy - October 2017 - Impact of Inpatient Automatic Therapeutic Substitutions on Postdischarge Medication Prescribing
Hospital Pharmacy - October 2017 - 634
Hospital Pharmacy - October 2017 - 635
Hospital Pharmacy - October 2017 - 636
Hospital Pharmacy - October 2017 - 637
Hospital Pharmacy - October 2017 - Impact of Respiratory Viral Panel Polymerase Chain Reaction Assay Turnaround Time on Length of Stay and Antibiotic Use in Patients With Respiratory Viral Illnesses
Hospital Pharmacy - October 2017 - 639
Hospital Pharmacy - October 2017 - 640
Hospital Pharmacy - October 2017 - 641
Hospital Pharmacy - October 2017 - 642
Hospital Pharmacy - October 2017 - Administration of Injectable Vitamin K Orally
Hospital Pharmacy - October 2017 - 644
Hospital Pharmacy - October 2017 - 645
Hospital Pharmacy - October 2017 - 646
Hospital Pharmacy - October 2017 - 647
Hospital Pharmacy - October 2017 - 648
Hospital Pharmacy - October 2017 - 649
Hospital Pharmacy - October 2017 - 650
Hospital Pharmacy - October 2017 - 651
Hospital Pharmacy - October 2017 - 652
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2020
https://www.nxtbook.com/nxtbooks/sage/psychologicalscience_demo
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2020
https://www.nxtbook.com/nxtbooks/sage/fai_202009
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_august2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2019
https://www.nxtbook.com/nxtbooks/sage/fai_201909
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_july2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2019
https://www.nxtbook.com/nxtbooks/sage/canadianpharmacistsjournal_05062019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2019
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201903
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2018
https://www.nxtbook.com/nxtbooks/sage/tec_20180810
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2018
https://www.nxtbook.com/nxtbooks/sage/fai_201807
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2018
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201803
https://www.nxtbook.com/nxtbooks/sage/slas_discovery_201712
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_november2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_september2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2017
https://www.nxtbook.com/nxtbooks/sage/fai_supplement_201709
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_may2017
https://www.nxtbook.com/nxtbooks/sage/fai_201706
https://www.nxtbook.com/nxtbooks/sage/fai_201607
https://www.nxtbookmedia.com